UNSPSC 51383505: Oxametacin or oxamethacin

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H17ClN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8G02RSW5CM, chemically known as 1h-indole-3-acetamide, 1-(4-chlorobenzoyl)-n-hydroxy-5-methoxy-2-methyl- (9ci) but generally known as oxametacin, which bears US NIH Compound Identifier 33675. European Medicines Agency schedules Oxametacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09492MIG.

UNSPSC 51383505 Oxametacin or oxamethacin, a Commodity code, shows minimal recent state and local procurement activity aligned with its pharmaceutical scope. The single recent opportunity on record — Seminole County, Florida's IFB 60459723LAS — requests naloxone and safe drug deactivation systems rather than oxametacin, indicating a significant mismatch between the code's nominal pharmaceutical classification and the work actually being solicited under it. Naloxone is an opioid antagonist used in overdose response, fundamentally different from oxametacin's anti-inflammatory mechanism. State and local buyers do source pharmaceuticals and medical supplies through procurement channels, but this code does not currently reflect meaningful activity in those categories based on available opportunity records.

Seminole County's naloxone procurement, posted June 30, 2026 with an IFB response deadline of July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carried a two-year initial term with a one-year renewal option, E-Verify compliance requirements, drug-free workplace certification, and potential FEMA funding with accompanying federal compliance obligations. No other recent state or local solicitations under this code are documented. The code shows limited current pursuit potential for vendors in the pharmaceutical or medical-supply space unless activity expands beyond the single unrelated opportunity now on record.